EU antitrust regulators will rule by July 27 whether to clear Illumina’s proposed US$7.1 billion acquisition of cancer test maker Grail Inc, a European Commission filing showed on Thursday, June 17.
US life sciences company Illumina, which is also challenging the EU watchdog’s decision to review the deal even though it does not meet the EU revenue criteria, filed for EU approval on Wednesday.
The company has stated it will pursue a dual-track tactic, launching litigation against the Commission while following the EU merger process.
The EU competition enforcer can clear the deal with or without demanding concessions. It can open a four-month investigation if it has serious concerns.
It has stated the combined entity could restrict access to, or increase prices of, next-generation sequencers and reagents to the detriment of Grail rivals in genomic cancer tests.
Illumina announced the deal to buy out investors including Amazon founder Jeff Bezos last September. It spun off Grail as a separate business four years ago, but remained the company’s largest shareholder.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Cisco Closes $28 Billion Splunk Deal
Mar 19, 2024 by
CPI
Ropes & Gray Strengthens Antitrust Practice with New Partner
Mar 19, 2024 by
CPI
Biden Administration Supports Antitrust Suit Against FIFA
Mar 18, 2024 by
CPI
Apple in Talks to Incorporate Google’s Gemini AI Amid Antitrust Scrutiny
Mar 18, 2024 by
CPI
Appeals Court Revives Regeneron’s Antitrust Lawsuit Against Novartis Over Vision Treatment
Mar 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pricing Algorithms
Feb 28, 2024 by
CPI
Pricing Algorithms and Antitrust Enforcement: Sandboxes to the Rescue?
Feb 28, 2024 by
CPI
AI, Algorithmic Pricing, and Collusion
Feb 28, 2024 by
CPI
Competition & Collusion in a World of Algorithmic Pricing: Antitrust Risks & Enforcement Trends
Feb 28, 2024 by
CPI
Pricing Algorithms in Antitrust’s Sights?
Feb 28, 2024 by
CPI